SND Rs1799889(-) In The Promotor Of The Plasminogen Activator Inhibitor-1 Gene Contributes To The Risk Of DVT In Women

1. Rosendaal F. Venous thrombosis: amulticausal disease. Lancet. 1999;353(9159):1167-73.10.1016/S0140-6736(98)10266-0Search in Google Scholar

2. Kujovich J. Factor V Leiden thrombophilia. Genet Med. 2011;13(1):1-16.10.1097/GIM.0b013e3181faa0f2Search in Google Scholar

3. Rodger M, Wells PS. Diagnosis of pulmonary embolism. Thromb Res. 2001;103(6):225-38.10.1016/S0049-3848(01)00326-7Search in Google Scholar

4. Stiko A, Hervio L, Loskutoff DJ. Plasminogen activator inhibitors. In: Colleman RW, Hirsh J, Marder VJ, Clowes AW, George JN, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Pa: Lippincott Williams and Wilkins; 2001. p. 975-1002. 2002.Search in Google Scholar

5. Smith EB. Haemostatic risk factors for cardiovascular diseases. 1998;19:39-43.Search in Google Scholar

6. Olié V, Zhu T, Martinez I, Scarabin P-Y, Emmerich J. Sex-specific risk factors for recurrent venous thromboembolism. Thromb Res. 2012;130(1):16-20.10.1016/j.thromres.2011.10.02622100316Search in Google Scholar

7. Bates SM, Jaeschke R, Stevens SM, Goodacre S, Wells PS, Stevenson MD, et al. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis. 2012;141(2):351-418.Search in Google Scholar

8. Wilbur J, Shian B. Diagnosis of DVT, Am Fam Physician. 2012:86(10):913-9.Search in Google Scholar

9. Komsa-Penkova R, Kovacheva- Kotseva K, Angelova S, Savov A, Semionova M. Selected methods of DNA analysis and clinical applications. Pleven: MU – Pleven; 2004.Search in Google Scholar

10. Kwok S, Higuchi R. Avoiding false-positives with PCR. Nature. 1989;339(6221):237-8.10.1038/339237a02716852Search in Google Scholar

11. Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis: a meta-analysis. Thromb Haemost. 2007;97(6):907-13.10.1160/TH06-12-0745Search in Google Scholar

12. Ivanov P, Komsa-Penkova R, Ivanov Y, Ivanov I, Matkov O, Beshev L. [Polymorphism in 4G/5G in the plasminogen activator inhibitor-1 gene in patients with DVT]. Savremenna Medicina. 2009;60(2):35-9. BulgarianSearch in Google Scholar

13. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation. 2000;101(1):67-70.10.1161/01.CIR.101.1.6710618306Search in Google Scholar

14. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001;104(25):3063-8.10.1161/hc5001.10079311748101Search in Google Scholar

15. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth WT Jr, Reiner AP. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9(2):131-7.10.1177/17418267020090020912006921Search in Google Scholar

16. Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003;34:2822-810.1161/01.STR.0000098004.26252.EB14605330Search in Google Scholar

17. Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slagboom PE. Angiotensin I–converting enzyme and plasminogen activator inhibitor–1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol. 1999;34:1176-83.10.1016/S0735-1097(99)00337-XSearch in Google Scholar

18. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, de Groot PG, Sixma JJ, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. 2000;101:67-70.Search in Google Scholar

19. Argirios E, Tsantes A, Georgios K, Nikolopoulos B, Pantelis G, Bagos S, et al. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res. 2008;122:736-4210.1016/j.thromres.2007.09.00517949795Search in Google Scholar

20. Komsa-Penkova R, Ivanov Y, Tonchev P, Ivanov P, Golemanov G, Kovacheva K, et al. Predisposition to thrombophilia and hypofibrinolysis in pulmonary embolism: analysis of inherited factors. J Boimed Clin Res. 201;6(2):73-81.10.1515/jbcr-2015-0105Search in Google Scholar

21. Saucedo R, Basurto L, Zarate A, Martínez C, Hernandez M, Galván R. Effect of Estrogen Therapy on Insulin Resistance and Plasminogen Activator Inhibitor Type 1 Concentrations in Postmenopausal Women. Gynecol Obstet Invest. 2007;64(2):61-410.1159/00009914817264514Search in Google Scholar